(Q46012957)

18 December 2017

title

Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. (English)

1 reference

18 December 2017

1 reference

8

1 reference

18 December 2017

author name string

Marco Breinig

1

1 reference

18 December 2017

Eloisi Caldas-Lopes

2

1 reference

18 December 2017

Benjamin Goeppert

3

1 reference

18 December 2017

Mona Malz

4

1 reference

18 December 2017

Ralf Rieker

5

1 reference

18 December 2017

Frank Bergmann

6

1 reference

18 December 2017

Peter Schirmacher

7

1 reference

18 December 2017

Gabriela Chiosis

9

1 reference

18 December 2017

Michael André Kern

10

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

18 December 2017

published in

Hepatology

1 reference

18 December 2017

volume

50

1 reference

18 December 2017

issue

1

1 reference

18 December 2017

page(s)

102-112

1 reference

18 December 2017

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

cites work

1 reference

The Hsp90 molecular chaperone: an open and shut case for treatment

21 January 2018

1 reference

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

21 January 2018

1 reference

Targeting multiple signal transduction pathways through inhibition of Hsp90.

21 January 2018

1 reference

Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer

21 January 2018

1 reference

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

Focus on hepatocellular carcinoma.

21 January 2018

1 reference

Hepatocellular carcinoma pathogenesis: from genes to environment

21 January 2018

1 reference

Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer

21 January 2018

1 reference

Abnormal structure and expression of p53 gene in human hepatocellular carcinoma

21 January 2018

1 reference

Establishment and characterization of a nontumorigenic cell line derived from a human hepatocellular adenoma expressing hepatocyte-specific markers

21 January 2018

1 reference

In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

21 January 2018

1 reference

Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action

21 January 2018

1 reference

The biochemistry of apoptosis

21 January 2018

1 reference

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

21 January 2018

1 reference

Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1

21 January 2018

1 reference

Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin

21 January 2018

1 reference

Functional genomics of hepatocellular carcinoma

21 January 2018

1 reference

Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

21 January 2018

1 reference

Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis

21 January 2018

1 reference

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

21 January 2018

1 reference

Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma.

21 January 2018

1 reference

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers

21 January 2018

1 reference

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

Targeting Hsp90: small-molecule inhibitors and their clinical development

21 January 2018

1 reference

Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function

21 January 2018

1 reference

Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice

21 January 2018

1 reference

Cyclin E overexpression responsible for growth of human hepatic tumors with p21WAF1/CIP1/SDI1

21 January 2018

1 reference

7 January 2021

Differential expression of E-prostanoid receptors in human hepatocellular carcinoma

1 reference

7 January 2021

Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications

1 reference

7 January 2021

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

7 January 2021

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22912

1 reference

18 December 2017

1 reference

18 December 2017